drugset / Trial / NCT06896760

A Mass Balance Study of [14C]ABSK011

NCT06896760

Phase 1 Not yet recruiting 6 enrolled Abbisko Therapeutics Co, Ltd
NaSingle-groupOpen-labelTreatment

Summary

This study is a single-site, open-label, single-cohort, single-dose study to assess the absorption, metabolism, and excretion profile of \[14C\] ABSK011 in healthy adult male subjects. The study plans to enroll 6 to 8 healthy male subjects to ensure at least 6 evaluable subjects.

Timeline

Start
2025-04-07
Primary completion
2025-11-07
Completion
2026-04-07

Drugs

EvaluationDrugModalityDoseRoute
Subject ABSK-011 Unknown 200 mg Oral

Indications

No indication recorded.